68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging

Abstract

Ga-DOTATATE PET/CT is superior to In-octreotide SPECT/CT for the detection of recurrent MTC demonstrating a significantly higher number of lesions.Ga-DOTATATE PET/CT showed a superior detection rate compared to CI in demonstrating bone metastases.

Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis

“…Nine articles were selected and retrieved in full-text version. [21][22][23][24][25][26][27][28][29] No additional studies were found screening the references of these articles. All nine articles eligible for the qualitative analysis (systematic review) were included in the quantitative analysis (meta-analysis) because all had sufficient data to assess the diagnostic performance of somatostatin receptor PET ( Figure 1).…”

“…[21][22][23][24][25][26][27][28][29] Six articles were retrospective (67%) and three were prospective (33%). Several countries of Europe, Asia and America were represented.…”

“…On the other hand, Yamaga et al found a significantly higher number of MTC lesions detected by somatostatin receptor PET compared to somatostatin receptor scintigraphy performed with tomographic acquisition (SPECT/CT), 21 while Ozkan et al found a significant number of MTC lesions detected by somatostatin receptor PET compared to scintigraphy with technetium-99m -labelled pentavalent dimercaptosuccinic acid ( 99m Tc-(V)DMSA).…”

“…To date, several studies have used somatostatin receptor PET in patients with recurrent MTC with conflicting results in terms of DR. [21][22][23][24][25][26][27][28][29] These studies have limited power, analyzing only relatively small numbers of MTC patients. In order to derive more robust estimates of diagnostic performance of somatostatin receptor PET in this setting we have pooled published studies.…”

SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

“…Inoctreotide SPECT/CT and conventional imaging^published in the European Journal of Nuclear Medicine and Molecular Imaging [1]. It is focused on the comparison between different diagnostic imaging methods in order to investigate their effectiveness in localizing recurrent medullary thyroid carcinoma (MTC).…”